Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $16
Cogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy Rating
Express News | Cogent Biosciences Announces Pipeline Expansion Into Kras and Poster Presentations at the 2024 Eortc-Nci-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Cogent Biosciences Announces Pipeline Expansion Into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $15
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth
Express News | Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $10
Cogent Biosciences, Inc. (COGT): This Small-Cap Healthcare Stock Is A Good Buy Right Now
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $13 to $22
Positive Outlook for Cogent Biosciences Backed by Clinical Trial Progress and Efficient Management
Express News | Cogent Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $17 From $19
Express News | Cogent Biosciences Inc: Peak Interim Futility Analysis Completed With No Changes to Study
Express News | Cogent Biosciences Inc: Top-Line Results Expected by End of 2025
Express News | Cogent Biosciences Announces Phase 3 Peak Trial in Patients With Gastrointestinal Stromal Tumors (Gist) Has Completed Enrollment and Advanced Past Interim Futility Analysis
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients With Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
Hold Rating on Cogent Biosciences Amid Competitive Landscape and Anticipated Milestones
Cogent Biosciences Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Cogent Biosciences, Lowers Price Target to $19